Published in Int J Gynecol Cancer on May 01, 2011
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol (2015) 3.62
Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection. Clin Cancer Res (2013) 2.45
Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology (2012) 1.71
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther Adv Med Oncol (2014) 1.05
Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. Mod Pathol (2013) 1.04
Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol (2012) 1.01
Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. Gynecol Oncol (2013) 0.97
Role of aggressive surgical cytoreduction in advanced ovarian cancer. J Gynecol Oncol (2015) 0.95
Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer. Gynecol Oncol (2013) 0.90
Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study. J Gynecol Oncol (2014) 0.88
Patient preferences in advanced or recurrent ovarian cancer. Cancer (2014) 0.85
Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. Gynecol Oncol (2016) 0.84
SEOM guideline in ovarian cancer 2014. Clin Transl Oncol (2014) 0.84
Clinical trials with pegylated liposomal Doxorubicin in the treatment of ovarian cancer. J Drug Deliv (2013) 0.83
Negative trials in ovarian cancer: is there such a thing as too much optimism? Ecancermedicalscience (2016) 0.83
Multi-center evaluation of post-operative morbidity and mortality after optimal cytoreductive surgery for advanced ovarian cancer. PLoS One (2012) 0.82
Update on first-line treatment of advanced ovarian carcinoma. Int J Womens Health (2013) 0.82
Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy? Gynecol Oncol (2017) 0.82
Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer. Chin J Cancer (2015) 0.81
Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer. Oncotarget (2015) 0.81
Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer. Geburtshilfe Frauenheilkd (2013) 0.81
Different sequential approaches of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treating ovarian cancer with malignant ascites. J Cancer Res Clin Oncol (2014) 0.79
Resistance to glucose starvation as metabolic trait of platinum-resistant human epithelial ovarian cancer cells. Oncotarget (2016) 0.77
The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer. PLoS One (2016) 0.76
GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012. Clin Transl Oncol (2013) 0.76
Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease. Genes Cancer (2015) 0.76
Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin. Clin Exp Metastasis (2015) 0.76
17β-estradiol inhibits spreading of metastatic cells from granulosa cell tumors through a non-genomic mechanism involving GPER1. Carcinogenesis (2015) 0.75
A review of patient and carer participation and the use of qualitative research in the development of core outcome sets. PLoS One (2017) 0.75
The cost-effectiveness of bevacizumab for the treatment of advanced ovarian cancer in Canada. Curr Oncol (2016) 0.75
Gynecologic Malignancies in Pregnancy: Balancing Fetal Risks With Oncologic Safety. Obstet Gynecol Surv (2017) 0.75
The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer. Radiol Oncol (2016) 0.75
Preference of elderly patients' to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial. Gynecol Oncol Res Pract (2017) 0.75
Selecting the best strategy of treatment in newly diagnosed advanced-stage ovarian cancer patients. World J Methodol (2015) 0.75
Primary ovarian cancer cell inhibition by human Wharton's Jelly stem cells (hWJSCs): Mapping probable mechanisms and targets using systems oncology. Bioinformation (2015) 0.75
The Relevance of Gynecologic Oncologists to Provide High-Quality of Care to Women with Gynecological Cancer. Front Oncol (2016) 0.75
SEOM Clinical Guideline in ovarian cancer (2016). Clin Transl Oncol (2016) 0.75
Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines. Am J Cancer Res (2016) 0.75
Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report. Onco Targets Ther (2017) 0.75
Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian, tubal, and peritoneal cancers. Int J Clin Oncol (2015) 0.75
Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center. Gynecol Oncol (2016) 0.75
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet (2010) 9.72
Epigenetic stem cell signature in cancer. Nat Genet (2006) 9.62
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet (2010) 8.41
A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med (2005) 6.86
Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res (2010) 6.03
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 5.57
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol (2009) 5.37
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med (2012) 5.31
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res (2005) 4.02
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 3.98
Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet (2003) 3.89
BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol (2012) 3.86
FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res (2007) 3.79
Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet (2002) 3.58
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol (2013) 3.56
Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study. BMJ (2008) 3.32
Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res (2004) 3.23
Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol (2010) 2.91
Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst (2004) 2.79
Barriers to racial/ethnic minority application and competition for NIH research funding. J Natl Med Assoc (2005) 2.60
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
hCDC4 gene mutations in endometrial cancer. Cancer Res (2002) 2.36
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol (2005) 2.33
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol (2008) 2.28
The Y deletion gr/gr and susceptibility to testicular germ cell tumor. Am J Hum Genet (2005) 2.26
Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Hum Mol Genet (2006) 2.23
DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res (2003) 2.14
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer (2011) 2.09
Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res (2006) 1.99
Circulating tumor cells in metastatic breast cancer--toward individualized treatment? N Engl J Med (2004) 1.89
Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer. Cancer Biol Ther (2010) 1.85
A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer (2006) 1.82
IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res (2011) 1.79
DNA hypomethylation and ovarian cancer biology. Cancer Res (2004) 1.75
Cancer-related fatigue in women with breast cancer: outcomes of a 5-year prospective cohort study. J Clin Oncol (2012) 1.73
Assessing health-related quality of life in gynecologic oncology: a systematic review of questionnaires and their ability to detect clinically important differences and change. Int J Gynecol Cancer (2010) 1.72
Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients. Breast Cancer Res Treat (2011) 1.71
Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial. Gynecol Oncol (2012) 1.70
The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. Urol Oncol (2009) 1.70
Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol (2006) 1.69
Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol (2014) 1.69
Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res (2005) 1.62
Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res (2008) 1.60
The fertility-related concerns, needs and preferences of younger women with breast cancer: a systematic review. Breast Cancer Res Treat (2009) 1.52
Herpes simplex virus infection of dendritic cells: balance among activation, inhibition, and immunity. J Infect Dis (2003) 1.46
Detection of human papillomavirus DNA in breast cancer of patients with cervical cancer history. J Clin Virol (2004) 1.45
Heterogeneous cross-talk of E2F family members is crucially involved in growth modulatory effects of interferon-gamma and EGF. Cancer Biol Ther (2006) 1.44
International brachytherapy practice patterns: a survey of the Gynecologic Cancer Intergroup (GCIG). Int J Radiat Oncol Biol Phys (2010) 1.44
Improving cancer outcomes through international collaboration in academic cancer treatment trials. J Clin Oncol (2009) 1.43
Clinical relevance of E2F family members in ovarian cancer--an evaluation in a training set of 77 patients. Clin Cancer Res (2007) 1.40
L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst (2013) 1.40
LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. Cancer Res (2012) 1.39
Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve (2005) 1.37
Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res (2004) 1.36
Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clin Cancer Res (2002) 1.34
Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol (2004) 1.33
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol (2011) 1.31
Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol (2003) 1.31
Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer (2011) 1.27
Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a Defined personal and family history in an Ashkenazi Jewish woman (LAMBDA). Breast Cancer Res (2003) 1.25
It's now or never: fertility-related knowledge, decision-making preferences, and treatment intentions in young women with breast cancer--an Australian fertility decision aid collaborative group study. J Clin Oncol (2011) 1.20
Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. J Clin Oncol (2004) 1.20
Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas. J Pathol (2010) 1.20
Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study. Oncologist (2009) 1.19
Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease. Blood (2006) 1.18
The role of BRCA mutation testing in determining breast cancer therapy. Nat Rev Clin Oncol (2010) 1.18
Fatigue states after cancer treatment occur both in association with, and independent of, mood disorder: a longitudinal study. BMC Cancer (2006) 1.16
The fertility- and menopause-related information needs of younger women with a diagnosis of breast cancer: a qualitative study. Psychooncology (2003) 1.14
Effect of testing for human papillomavirus as a triage during screening for cervical cancer: observational before and after study. BMJ (2006) 1.14
DNA methylation in serum and tumors of cervical cancer patients. Clin Cancer Res (2004) 1.06
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. Int J Gynecol Cancer (2016) 1.06
Conservative management of abnormally invasive placenta: four case reports. Acta Obstet Gynecol Scand (2013) 1.06
Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer. Gynecol Oncol (2004) 1.06
Expression of the E2F family of transcription factors and its clinical relevance in ovarian cancer. Ann N Y Acad Sci (2006) 1.06
Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo. Clin Cancer Res (2005) 1.05
Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumors. Genes Chromosomes Cancer (2008) 1.05
Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda. Breast Cancer Res (2008) 1.05
First-line therapy in ovarian cancer trials. Int J Gynecol Cancer (2011) 1.03
Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary. Int J Gynecol Cancer (2014) 1.03
Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet (2012) 1.03
Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment. Wien Med Wochenschr (2010) 1.02
Mammaglobin expression in gynecologic malignancies and malignant effusions detected by nested reverse transcriptase-polymerase chain reaction. Lab Invest (2002) 1.02
Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma. Int J Gynecol Cancer (2014) 1.01
Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study. Ann Oncol (2011) 1.00
Oxaliplatin and axonal Na+ channel function in vivo. Clin Cancer Res (2006) 1.00
Favorable prognostic value of SOCS2 and IGF-I in breast cancer. BMC Cancer (2007) 1.00
Methylated DNA collected by tampons--a new tool to detect endometrial cancer. Cancer Epidemiol Biomarkers Prev (2004) 0.99
Relevance of gamma-glutamyltransferase--a marker for apoptotic balance--in predicting tumor stage and prognosis in cervical cancer. Gynecol Oncol (2011) 0.99
Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. J Natl Cancer Inst (2004) 0.99
Cyclin E dysregulation and chromosomal instability in endometrial cancer. Oncogene (2004) 0.99